查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1911944

抗血栓药物市场规模、份额和成长分析（按类型、药物类别、适应症、给药途径、最终用户和地区划分）－2026-2033年产业预测

Antithrombotic Drugs Market Size, Share, and Growth Analysis, By Type (Apixaban, Debigatran), By Drug Class (Thrombolytic Drugs, Anti-Platelet Drugs), By Indication, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033.
出版日期: | 出版商: SkyQuest | 英文 176 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到 2024 年，全球抗血栓药物市场规模将达到 522.2 亿美元，到 2025 年将达到 563.5 亿美元，到 2033 年将达到 1035.3 亿美元，预测期（2026-2033 年）的复合年增长率为 7.9%。

抗血栓药物市场受到心血管疾病盛行率上升、老年人口不断增长以及对新型口服抗凝血药物（NOACs）需求日益增长的显着影响。心血管疾病，包括心房颤动和静脉血栓栓塞症，是全球主要的死亡原因，这进一步增加了对有效抗血栓治疗的需求。老年人群尤其容易患血栓性疾病，从而扩大了患者群体。Dabigatran和利伐沙班等NOACs因其使用方便、药物交互作用少、出血风险低而迅速普及，推动了市场扩张。然而，出血风险增加、NOACs价格昂贵、消化器官系统併发症、严格的监管以及对副作用的担忧等挑战仍然限制市场成长。

全球抗血栓药物市场驱动因素

心房颤动、深层静脉栓塞症和中风等心血管疾病发生率的不断上升，是推动抗血栓药物需求成长的主要因素。人口增长、久坐的生活方式以及METABOLIC INC.症候群的流行等因素共同凸显了抗凝血和抗血小板药物的重要性。这些治疗方法不仅对急性疾病的即时控制至关重要，而且对长期降低心血管风险也至关重要。随着人们对这些健康问题的认识不断提高，抗血栓药物市场预计将会扩大，这反映了对有效治疗方案的需求。

限制全球抗血栓药物市场的因素

由于抗血栓药物本身存在出血风险，尤其是在老年患者和合併其他疾病的患者中，抗血栓药物市场面临严峻的挑战。这种风险的增加使临床决策更加复杂，可能需要持续监测、调整剂量，甚至停止治疗。此类安全隐患会削弱医疗服务提供者的信心，并导致病患依从性降低。因此，这些因素会对抗血栓治疗的整体市场渗透率和长期维持治疗的疗效产生深远的影响，最终影响患者的治疗结果。

全球抗血栓药物市场趋势

全球抗血栓市场正经历着向新一代标靶治疗的重大转变，这些疗法有望在凝血因子调节方面实现更高的特异性。这种创新方法专注于开发超标靶治疗方法，以降低出血风险并提供持久的治疗效果。透过针对特定的疾病进程，这些先进的抗血栓药物旨在最大限度地减少与传统疗法相关的副作用，并为更个人化的治疗策略铺平道路。因此，医疗专业人员能够更好地平衡凝血预防和出血控制，从而满足患者不断变化的需求，并推动抗血栓市场的成长。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二手资料和一手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2025）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析
  • 案例研究
  • 顾客购买行为分析

全球抗血栓药物市场规模（按类型和复合年增长率划分）（2026-2033 年）

  • Apixaban
  • 德比加特兰
  • 艾多沙班
  • 磺达肝癸钠
  • 肝素
  • Rivaroxaban

全球抗血栓药物市场规模（依药物类别划分）及复合年增长率（2026-2033 年）

  • 溶栓药物
  • 抗血小板药物
  • 抗凝血剂
  • 其他的

全球抗血栓药物市场规模（按适应症和复合年增长率划分）（2026-2033 年）

  • 心房颤动
  • 中风
  • 深层静脉栓塞症（DVT）
  • 肺动脉栓塞（PE）
  • 其他的

全球抗血栓药物市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

  • 口服
  • 注射
  • 其他的

全球抗血栓药物市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

  • 医院
  • 专科诊所
  • 居家医疗
  • 其他的

全球抗血栓药物市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

  • 医院药房
  • 零售药房
  • 网路药房
  • 其他的

全球抗血栓药物市场规模及复合年增长率（2026-2033）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2025 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2025 年）
  • 主要企业公司简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2023-2025年营收年比比较

主要企业简介

  • F. Hoffmann-La Roche Ltd.（Switzerland）
  • Teva Pharmaceutical Industries Ltd.（Ireland）
  • Sanofi（France）
  • Pfizer Inc.（US）
  • GlaxoSmithKline plc（UK）
  • Novartis AG（Switzerland）
  • Merck & Co., Inc.（US）
  • Allergan（Ireland）
  • AstraZeneca（UK）
  • Johnson & Johnson Private Limited（US）
  • Hikma Pharmaceuticals PLC（UK）
  • Fresenius Kabi AG（Germany）
  • Eisai Co., Ltd.（Japan）
  • Bristol-Myers Squibb Company（US）
  • Bayer AG（Germany）
  • DAIICHI SANKYO COMPANY, LIMITED（Japan）

结论与建议

简介目录
Product Code: SQMIG35I2432

Global Antithrombotic Drugs Market size was valued at USD 52.22 Billion in 2024 and is poised to grow from USD 56.35 Billion in 2025 to USD 103.53 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

The market for antithrombotic drugs is significantly influenced by the increasing prevalence of cardiovascular diseases, a growing geriatric population, and a rising demand for novel oral anticoagulants (NOACs). Cardiovascular conditions, including atrial fibrillation and venous thromboembolism, represent a leading cause of mortality globally, thereby heightening the need for effective antithrombotic therapies. The elderly are particularly susceptible to thrombotic disorders, expanding the patient demographic. The popularity of NOACs, such as dabigatran and rivaroxaban, is surging due to their ease of use, minimal drug interactions, and lower bleeding risks, which is propelling market expansion. However, challenges like heightened bleeding risks, the high expense of NOACs, gastrointestinal complications, stringent regulations, and apprehension about side effects continue to constrain market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antithrombotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antithrombotic Drugs Market Segments Analysis

Global Antithrombotic Drugs Market is segmented by Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin and Rivaroxaban. Based on Drug Class, the market is segmented into Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants and Others. Based on Indication, the market is segmented into Atrial Fibrillation, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE) and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antithrombotic Drugs Market

The increasing incidence of cardiovascular conditions such as atrial fibrillation, deep vein thrombosis, and stroke significantly drives the demand for antithrombotic drugs. Contributing factors include an expanding population, sedentary lifestyles, and the prevalence of metabolic syndrome, which together highlight the critical role of anticoagulants and antiplatelet medications. These therapies are essential not only for the immediate management of acute events but also for the long-term reduction of cardiovascular risks. As awareness of these health issues continues to rise, the market for antithrombotic medications is expected to expand, reflecting the need for effective treatment options.

Restraints in the Global Antithrombotic Drugs Market

The Global Antithrombotic Drugs market faces significant challenges due to the inherent risk of bleeding associated with these medications, particularly for elderly patients or individuals with pre-existing health conditions. This elevated risk complicates clinical decision-making processes, often necessitating continuous monitoring, adjustments in dosage, or even discontinuation of therapy. Such safety concerns can undermine the confidence of healthcare providers and lead to decreased patient adherence to prescribed regimens. Consequently, these factors can severely impact both the overall market penetration of antithrombotic treatments and the effectiveness of long-term maintenance therapies, ultimately affecting patient outcomes.

Market Trends of the Global Antithrombotic Drugs Market

The global antithrombotic drugs market is witnessing a notable trend toward next-generation targeted therapies that promise enhanced specificity in coagulation factor modulation. This innovative approach is focused on developing ultra-targeted treatments with reduced bleeding risks and sustained therapeutic efficacy. By honing in on specific pathological processes, these advanced antithrombotic agents are designed to minimize side effects associated with traditional therapies, paving the way for more personalized treatment strategies. As a result, healthcare providers can better balance the prevention of clotting with the control of bleeding, meeting the evolving needs of patients and driving growth in the antithrombotic market.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Customer Buying Behavior Analysis

Global Antithrombotic Drugs Market Size by Type & CAGR (2026-2033)

  • Market Overview
  • Apixaban
  • Debigatran
  • Edoxaban
  • Fondaparinux
  • Heparin
  • Rivaroxaban

Global Antithrombotic Drugs Market Size by Drug Class & CAGR (2026-2033)

  • Market Overview
  • Thrombolytic Drugs
  • Anti-Platelet Drugs
  • Anticoagulants
  • Others

Global Antithrombotic Drugs Market Size by Indication & CAGR (2026-2033)

  • Market Overview
  • Atrial Fibrillation
  • Stroke
  • Deep vein thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others

Global Antithrombotic Drugs Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Oral
  • Injectable
  • Others

Global Antithrombotic Drugs Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Global Antithrombotic Drugs Market Size by Distribution Channel & CAGR (2026-2033)

  • Market Overview
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Global Antithrombotic Drugs Market Size & CAGR (2026-2033)

  • North America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • US
    • Canada
  • Europe (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd. (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (U.K.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (U.K.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson Private Limited (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hikma Pharmaceuticals PLC (U.K.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fresenius Kabi AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eisai Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • DAIICHI SANKYO COMPANY, LIMITED (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations